Krystal Biotech, Inc. KRYS Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s operating lease liabilities (current)?
- Krystal Biotech, Inc. (KRYS) reported operating lease liabilities (current) of $1.8M in Q1 2026.
- How has Krystal Biotech, Inc.'s operating lease liabilities (current) changed year-over-year?
- Krystal Biotech, Inc.'s operating lease liabilities (current) increased by 32.2% year-over-year, from $1.36M to $1.8M.
- What is the long-term trend for Krystal Biotech, Inc.'s operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s operating lease liabilities (current) has grown at a -19.1% compound annual growth rate (CAGR), from $5.11M to $1.77M.
- What does operating lease liabilities (current) mean?
- The amount of rent or lease payments due within the next year.
- How do you interpret operating lease liabilities (current)?
- An increase reflects expanding physical footprint or rising lease costs, while a decrease suggests a reduction in leased facilities or lease expirations.
- How does operating lease liabilities (current) compare across companies?
- Standard for companies with significant physical infrastructure; highly comparable across firms following IFRS 16 or ASC 842.